Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.

SG&A Expenses: AstraZeneca vs. Rhythm Pharmaceuticals

__timestampAstraZeneca PLCRhythm Pharmaceuticals, Inc.
Wednesday, January 1, 2014133240000001213000
Thursday, January 1, 2015114510000003425000
Friday, January 1, 201697390000006311000
Sunday, January 1, 2017105430000009518000
Monday, January 1, 20181036200000028080000
Tuesday, January 1, 20191184800000036550000
Wednesday, January 1, 20201169300000046125000
Friday, January 1, 20211568000000068486000
Saturday, January 1, 20221895500000092032000
Sunday, January 1, 202318025000000117532000
Monday, January 1, 202420532000000
Loading chart...

Unleashing insights

A Decade of SG&A: AstraZeneca vs. Rhythm Pharmaceuticals

In the ever-evolving pharmaceutical industry, operational costs are a critical factor in determining a company's financial health. Over the past decade, AstraZeneca PLC and Rhythm Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. AstraZeneca, a global leader, has seen its SG&A expenses grow by approximately 35% from 2014 to 2023, peaking in 2022. This reflects its expansive global operations and strategic investments. In contrast, Rhythm Pharmaceuticals, a smaller player, has experienced a staggering 9,600% increase in SG&A expenses over the same period, indicative of its aggressive growth strategy and market penetration efforts. This comparison highlights the diverse strategies employed by pharmaceutical companies to manage operational costs while striving for market leadership.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025